Stay updated with breaking news from Douglas Lyon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Joseph Douglas Lyon sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $30.18, for a total transaction of $150,900.00. Following the completion of the transaction, the insider now owns 7,314 […]
StockNews.com lowered shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) from a strong-buy rating to a buy rating in a report published on Friday morning. Several other brokerages have also weighed in on CORT. Truist Financial increased their price objective on shares of Corcept Therapeutics from $42.00 to $44.00 and gave the stock a buy […]
StockNews.com lowered shares of Corcept Therapeutics (NASDAQ:CORT – Free Report) from a strong-buy rating to a buy rating in a research note published on Friday. Other equities research analysts have also issued research reports about the company. Truist Financial increased their price target on Corcept Therapeutics from $42.00 to $44.00 and gave the stock a […]
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Joseph Douglas Lyon sold 10,830 shares of the company’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $26.00, for a total transaction of $281,580.00. Following the transaction, the insider now owns 7,314 shares of the company’s stock, […]
Corcept Therapeutics (NASDAQ:CORT – Free Report) had its price objective upped by HC Wainwright from $38.00 to $40.00 in a research note published on Thursday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Corcept Therapeutics’ Q2 2024 earnings at $0.21 EPS, Q3 2024 earnings […]